Strides Arcolab gets USFDA nod for generic skin disease cream

Drug firm Strides Arcolab has received approval from the US health regulator to market its generic Imiquimod cream, used in treating skin diseases, in the American market.

The Bangalore-based company has received approval from the US Food and Drug Administration (USFDA) for Imiquimod cream, Strides Arcolab Ltd said in a statement.

"This is the first product approval from Beltapharm, the company's USFDA approved semi-solids facility in Milan, Italy. The product will be marketed directly by Strides in the US market," it added.

According to IMS data, the US market for generic Imiquimod cream is around USD 140 million.

Imiquimod cream is a topical skin cream indicated for the treatment of certain types of actinic keratoses (precancerous skin lesions) on the face or scalp, external genital and perianal warts in patients aged 12 years and more.

Strides shares were trading at Rs 624.75 apiece on the BSE, up 3.46 per cent from its previous close.

EDITORIAL OF THE DAY

  • Trade policies must not ring fence specific industry sectors

    Within days of the government setting a floor price for import of steel products to thwart countries such as China from undercutting local mills, gove

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Tushar Gandhi

A democracy must stand up for its people

We are the world’s most populous dem­ocracy, but behave in ...

Purnendu Ghosh

A curious and an innovative mind

Curiosity is hard-wired into our psyche. We all recognise that ...

Shona Adhikari

A good time for European art auctions

This week, we bring you interesting art news and the ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture